Site Editor

Rebecca Olin, MD, MS


Mark J. Levis, MD, PhD, on AML: First-in-Human Study of an FLT3 Inhibitor

Posted: Monday, June 7, 2021

Mark J. Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses phase I data on a FF-10101-01 FLT3 inhibitor, which has shown activity in patients with refractory or relapsed acute myeloid leukemia, including those with mutations resistant to gilteritinib and other FLT3 kinase inhibitors. The study may be an important first step in targeting a mutation associated with high relapse and low survival and remission rates.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.